Liquid Biopsy
News and reporting on cell-free DNA testing.
Freenome Nets $290M Investment From Roche
The company said the latest influx brings its total funding to more than $1 billion and will help the firm expand its cancer detection platform to multiple tumor types.
NeoGenomics Blood-Based Minimal Residual Disease Test Receives CE Mark
NeoGenomics subsidiary Inivata has also submitted the RaDaR test to the MolDx program in the US for reimbursement.Â
Grail Partners With Premier's PINC AI to Improve Patient Access to Blood-Based Multi-Cancer Test
PINC AI plans to adapt its clinical decision support platform to alert clinicians to patients who may benefit from early cancer detection via Galleri.
Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom
Premium
New companies claimed stakes during the year, established firms solidified their plans and data, and Grail launched the first genomic multi-cancer early detection test.
Biodesix Raises Approximately $16.3M in Sale of Common Shares, Amends $30M Term Loan
The term loan amendment includes modifications to restrictive financial covenants to provide the firm with additional financial flexibility.